II.2.2) Additional CPV code(s)

85100000

II.2.3) Place of performance

NUTS code:

UKH

Main site or place of performance:

ESNEFT Acute Sites

II.2.4) Description of the procurement

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to decision makers by 1st October 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.’<br/><br/>2. Contract Title and Reference <br/> <br/>Title: PSR Histopathology Insourcing Services <br/>Reference: ESNEFT3285 <br/><br/>3.The name and address of the registered office or principal place of <br/>business of the provider to whom an award is to be made. <br/> <br/>ID Medical Clinical Services <br/>Mill Square, Featherstone Road, Wolverton Mill, Milton Keynes, MK12 5ZD <br/><br/>4.A description of the relevant health care services to which the contract <br/>relates, including the most relevant CPV code <br/>The Trust is seeking a supplier to provide a dedicated Histopathology Consultant <br/>Reporting Service under an insourcing model. The service will support the <br/>reduction of reporting backlogs and delivery of agreed turnaround times while <br/>maintaining high clinical quality and compliance with NHS and Royal College of <br/>Pathologists (RCPath) standards. <br/> <br/>The supplier must demonstrate the ability to provide a flexible, scalable service <br/>that can be mobilised rapidly to respond to fluctuations in reporting demand. <br/>5.The approximate lifetime value of the contract. <br/> <br/> <br/>£128,571 ex Vat (£154,285.20 Inc Vat) <br/> <br/>* Subjected to volume on a Zero Commitment Contract<br/><br/>6. The dates between which the contract provides for the services to be <br/>provided <br/>Contract Period: 12 months (1st October 2026 to 30th September 2027) with an option to <br/>extend for a further 12 months.<br/><br/>7. The reasons for the dates referred to in paragraph 6, if that period is <br/>greater than 12 months <br/> <br/>Option to extend for a further 12 months. <br/> <br/> <br/>8.Details of the award decision-makers. <br/> <br/> <br/>The Histopathology/Pathology Service has followed all routes to source an <br/>insourced histology reporting service, in accordance with Trust policies and <br/>governance. <br/> <br/>Key individuals - East Suffolk and North Essex NHS Foundation Trust (ESNEFT): <br/> <br/>Sarah Stalley – Head of Pathology Operations – ESNEFT; Cross-site <br/> <br/>Chris Gratze – Histopathology Service Lead - ESNEFT; Cross-site. <br/> <br/>Neil Goryn - Divisional Finance Manager – ESNEFT; Cancer & Diagnostics <br/>division. <br/> <br/>Hanne Ness – Associated Director of Operations – ESNEFT Cancer & Diagnostics <br/>division <br/><br/>7.A statement explaining the award decision-makers’ reasons for selecting <br/>the chosen provider, with reference to the key criteria. <br/> <br/>Considered by the Division and guidance obtained to use PSR Regulations <br/> <br/>ID Medical Clinical Services completed a PSR Further Completion under the <br/>RM6281 Workforce Alliance Clinical and Healthcare Staffing framework <br/>https://workforcealliance.nhs.uk/. ID Medical Clinical Services were the successful <br/>applicant of the further completion and meet the set criteria. <br/> <br/>8.Any declared conflicts or potential conflicts of interest. <br/> <br/> <br/>None declared. <br/> <br/>9.Information as to how any conflicts or potential conflicts of interest were <br/>managed. <br/> <br/>All Key individuals at Section 6 completed and signed Declaration of interest Forms.

II.2.14) Additional information

This notification activates the mandatory 8-day standstill period under the Provider Selection Regime. The standstill period will conclude at 12:00 noon on 1st October 2026